SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-061113
Filing Date
2023-05-16
Accepted
2023-05-16 06:01:42
Documents
15
Period of Report
2023-05-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2315915d1_8k.htm   iXBRL 8-K 29481
2 EXHIBIT 5.1 tm2315915d1_ex5-1.htm EX-5.1 10046
3 EXHIBIT 10.1 tm2315915d1_ex10-1.htm EX-10.1 285434
4 GRAPHIC tm2315915d1_ex5-1img01.jpg GRAPHIC 2330
  Complete submission text file 0001104659-23-061113.txt   583293

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA otlk-20230515.xsd EX-101.SCH 3322
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20230515_lab.xml EX-101.LAB 34986
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20230515_pre.xml EX-101.PRE 22617
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2315915d1_8k_htm.xml XML 3695
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 23925449
SIC: 2836 Biological Products, (No Diagnostic Substances)